Orchestrating networks in the biopharmaceutical industry: Small hub firms can do it

Production Planning and Control

Volumn 21, Issue 2, 2010, Pages 218-228

  Sabatier, V ^a,b,c   Mangematin, V ^b   Rousselle, T ^c  

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE ECOLE DE MANAGEMENT   (France)

^c Px'Therapeutics   (France)

Author keywords

Biotechnology; Business model; Hub firm; Network; Value chain

Indexed keywords

BIOPHARMACEUTICAL INDUSTRY; BIOTECHNOLOGY COMPANIES; BUSINESS MODELS; DRUG DEVELOPMENT; FIRM NETWORK; HUB FIRM; OPTIMISATIONS; PRODUCTION PROCESS; START-UPS; VALUE CHAINS;

CORRELATION THEORY;

BIOTECHNOLOGY;

EID: 77749234181     PISSN: 09537287     EISSN: 13665871     Source Type: Journal    
DOI: 10.1080/09537280903441971     Document Type: Conference Paper

References (53)

1. Arora, A. and Gambardella, A., 1994a. The changing technology of technological change: general and abstract knowledge and the division of innovative labour. Research policy, 23, 523-532.
2. Arora, A. and Gambardella, A., 1994b. Evaluating technological information and utilizing it. Journal of Economic Behavior & Organization, 24, 91-114.
3. Arthurs, J.D. and Busenitz, L.W., 2006. Dynamic capabilities and venture performance: the effects of venture capitalists. Journal of Business Venturing, 21 (2), 195-215.
4. Bamfield, P., 2003. The structural components of an R & D organisation, Research and development management in the chemical and pharmaceutical industry. 2nd ed. Wiley-VCH.
5. Baum, J.A., Calabrese, T., and Silverman, B.S., 2000. Don't go it alone: alliance network composition and startups'performance in canadian biotechnology. Strategic Management Journal, 21, 267-294.
6. Bigras Y., 2002. How networked and virtual businesses are changing the way companies work together. CMA Management.
7. Brass, D.J. and Burkhardt, M.E., 1993. Potential power and power use: An investigation of structure and behavior. Academy of Management Journal, 36, 441-470.
8. Chesbrough, H.W. and Schwartz, K., 2007. Innovating business models with co-development partnerships. Research Technology Management, 50 (1), 55-59.
9. Chesbrough H.W. and Teece D.J., 1996. Organizing for innovation: when is virtual virtuous? Harvard Business Review.
10. Danzon, P.M., Nicholson, S., and Pereira, N.S., 2005. Productivity in pharmaceutical-biotechnology R & D: the role of experience and alliances. Journal of Health Economics, 24, 317-339.
11. Dhanaraj, C. and Parkhe, A., 2006. Orchestrating innovation networks. Academy of Management Review, 31 (3), 659-669.
12. DiMasi, J. and Grabowski, H.G., 2007. The cost of biopharmaceutical R & D: is biotech different? Managerial and Decision Economics, 28, 469-479.
13. DiMasi, J.A., et al., 1991. Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10, 107-142.
14. DiMasi, J.A., Hansen, R.W., and Grabowski, HG., 2003. The price of innovation: new estimates of drug development cost. Journal of Health Economics, 22, 151-185.
15. Durand, R., Bruyaka, O., and Mangematin, V., 2008. Do science and money go together? The case of the french biotech industry. Strategic Management Journal, 29 (12), 1281-1299.
16. Eisenhardt, K., 1989. Building theories from case study research. Academy of Management Review, 14 (4), 532-550.
17. Fisken, J. and Rutherford, J., 2002. Business models and investment trends in the biotechnology industry in Europe. Journal of Commercial Biotechnology, 8 (3), 191-199.
18. Gassmann, O. and Reepmeyer, G., 2005. Organizing pharmaceutical innovation: from Science-based knowledge creators to drug-oriented knowledge brokers. Creativity and Innovation Management, 14 (3), 233-245.
19. Gassmann, O., Reepmeyer, G., and von Zedtwitz, M., 2004. Leading Pharmaceutical Innovation, Trends and Drivers for Growth in the Pharmaceutical Industry. Berlin: Springer.
20. Govindarajan, V. and Gupta, A.K., 2001. Strategic innovation: a conceptual Road Map. Business Horizons, 44 (4), 3-12.
21. Hoan, H. and Rothaermel, F.T., 2005. The effect of general and partner-specific alliance experience on joint R & D project performance. Academy of Management Journal, 48 (2), 332-345.
22. Hopkins, M.M., et al., 2007. The myth of biotech revolution: an assessment of technological, clinical and organisational change. Research policy, 36 (4), 566-589.
23. Howells, J., Gagliardi, D., and Malik, K., 2008. The growth and management of R & D outsourcing: evidence from UK pharmaceuticals. R & D Management, 38 (2), 205-219.
24. Lane, C. and Probert, J., 2007. The external sourcing of technological knowledge by US Pharmaceutical companies: strategic goals and inter-organizational relationships. Industry and Innovation, 14 (1), 5-25.
25. Laroia, G. and Krishnan, S., 2005. Managing drug discovery alliances for success. Research Technology Management, 48 (5), 42-50.
26. Lee, Y.H., et al., 2006. Supply chain model for the semiconductor industry in consideration of manufacturing characteristics. Production Planning and Control, 17 (5), 518-533.
27. Liebeskind, J.P., et al., 1996. Social networks, learning, and flexibility: sourcing scientific knowledge in new biotechnology firms. Organization Science, 7 (4), 428-443.
28. Lorenzoni, G. and Baden-Fuller, C., 1995. Creating a strategic center to manage a web of partners. California Management Review, 37 (3), 146-163.
29. Orsenigo, L., et al., 1998. The evolution of knowledge and the dynamics of industry network. Journal of Management and Governance, 1, 147-175.
30. Osterwalder, A., Pigneur, Y., and Tucci, C.L., 2005. Clarifying business models: origins, present, and future of the concept. Communications of the Association for Information Systems, 15, 3-15.
31. Papadopoulos, S., 2000. Business models in biotech. Nature Biotechnology 18(Supplement).
32. Papania, L., et al., 2008. Using brand personality to assess whether biotechnology firms are saying the right things to their network. Journal of Commercial Biotechnology, 14 (3), 247-255.
33. Pettigrew, AM., 1990. Longitudinal field research on change: theory and practice. Organization Science, 1 (3), 267-292.
34. Pisano, G., 1990. The R & D boundaries of the firm: an empirical analysis. Administrative Science Quarterly, 35, 153-176.
35. Pisano, G., 2006. Can science be a business? Lessons from Biotech. Harvard Business Review, 84 (10), 114-125.
36. Pisano, G., Shan, W., and Teece, D.J., 1988. Joint ventures and collaboration in the biotechnology industry, In: D. Mowery, ed. International collaborative ventures in US manufacturing. Cambridge: Ballinger, 183-222.
37. Powell, W.W., 1990. Neither market nor hierarchy: network forms of organisation. Research in Organizational Behavior, 12, 295-336.
38. Powell, W.W., 1998. Learning from collaboration: knowledge and networks in the biotechnology and pharmaceutical industries. California Management Review, 40 (3), 228-240.
39. Powell, W.W., Koput, K.W., and Smith-Doerr, L., 1996. Interorganizational collaboration and the locus of innovation. Networks of learning in biotechnology. Administrative Science Quarterly, 41, 116-145.
40. Prencipe, A. and Tell, F., 2001. Interproject learning: processes and outcomes of knowledge codification in project-based firms. Research Policy, 30 (9), 1373-1394.
41. Rothaermel, F.T., 2001. Incumbent's advantage through exploiting complementary assets via interfirm cooperation. Strategic Management Journal, 22, 687-699.
42. Rothman, H. and Kraft, A., 2006. Downstream and into deep biology: evolving business models in 'top tier' genomics companies. Journal of Commercial Biotechnology, 12 (2), 86-98.
43. Rugman, A. and D'Cruz, J., 1997. The theory of the flagship firm. European Management Journal, 15 (4), 403-412.
44. Sabatier, V., Rousselle, T., and Mangematin, V., 2008. Going virtual in the European biopharmaceutical industry: conductors and oxpeckers make it. 9th working conference on virtual enterprises, Poznan, Poland, Springer.
45. Sawhney, M. and Parikh, D., 2001. Where values lives in a networked world. Harvard Business Review, 76-86.
46. Scarbrough, H., et al., 2004. Project-based learning and the role of learning boundaries. Organization Studies, 25 (9), 1579-1600.
47. Shan, W., Walker, G., and Kogut, B., 1994. Interfirm cooperation and startup innovation in the biotechnology industry. Strategic Management Journal, 15 (5), 387-394.
48. Siggelkow, N., 2007. Persuasion with case studies. Academy of Management Journal, 50(1), 20-24.
49. Teece, D.J., 1986. Profiting from technological innovation: implications for integration, collaboration, licensing and public policy. Research Policy, 15, 285-305.
50. Teece, D.J., 2000. Managing intellectual capital: Organizational, strategic, and policy dimensions. London: Oxford University Press.
51. Wasserman, S. and Galaskiewicz, J. (Eds.), 1994. Advances in social network analysis. London: Sage.
52. Weisenfeld, U., Reeves, J.C., and Hunck-Meiswinkel, A., 2001. Technology management and collaboration profile: virtual companies and industrial platforms in the high-tech biotechnology industries. R & D Management, 31 (1), 91-100.
53. Zhang, J., Baden-Fuller, C., and Mangematin, V., 2007. Technological knowledge base, R & D organization structure and alliance formation: evidence from the biopharmaceutical industry. Research Policy, 36, 515-528.